Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells

Nature Immunology volume 12, pages 975–983 (2011)Cite this article

Subjects

Abstract

APOBEC3G (A3G) is an intrinsic antiviral factor that inhibits the replication of human immunodeficiency virus (HIV) by deaminating cytidine residues to uridine. This causes guanosine-to-adenosine hypermutation in the opposite strand and results in inactivation of the virus. HIV counteracts A3G through the activity of viral infectivity factor (Vif), which promotes degradation of A3G. We report that viral protein R (Vpr), which interacts with a uracil glycosylase, also counteracted A3G by diminishing the incorporation of uridine. However, this process resulted in activation of the DNA-damage–response pathway and the expression of natural killer (NK) cell–activating ligands. Our results show that pathogen-induced deamination of cytidine and the DNA-damage response to virus-mediated repair of the incorporation of uridine enhance the recognition of HIV-infected cells by NK cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Expression of NKG2D ligands in HIV-infected cells.
Figure 2: Upregulation of A3G correlates with upregulation of NKG2D ligands.
Figure 3: Activation of the DNA-damage response in HIV-infected primary T cells.
Figure 4: HIV-infected T cells are resistant to recognition by NK cells unless an NKG2D ligand is overexpressed.
Figure 5: The effect of Vif on lysis by NK cells.
Figure 6: Vif and Vpr limit the incorporation of uridine into primary T cells.
Figure 7: Binding of UNG2 by Vpr induces the expression of NKG2D ligands.

Similar content being viewed by others

References

  1. Deeks, S.G. & Walker, B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).

    Article  CAS  Google Scholar 

  2. Peng, G., Lei, K.J., Jin, W., Greenwell-Wild, T. & Wahl, S.M. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203, 41–46 (2006).

    Article  CAS  Google Scholar 

  3. Chiu, Y.-L. & Greene, W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26, 317–353 (2008).

    Article  CAS  Google Scholar 

  4. Zhang, H. et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94–98 (2003).

    Article  CAS  Google Scholar 

  5. Bishop, K.N., Verma, M., Kim, E.-Y., Wolinsky, S.M. & Malim, M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231 (2008).

    Article  Google Scholar 

  6. An, P. et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J. Virol. 78, 11070–11076 (2004).

    Article  CAS  Google Scholar 

  7. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056–1060 (2003).

    Article  CAS  Google Scholar 

  8. Kijak, G.H. et al. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376, 101–111 (2008).

    Article  CAS  Google Scholar 

  9. Jern, P., Russell, R., Pathak, V. & Coffin, J. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5, e1000367 (2009).

    Article  Google Scholar 

  10. Goulder, P.J.R. & Watkins, D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8, 619–630 (2008).

    Article  CAS  Google Scholar 

  11. Schwartz, O., Maréchal, V., Le Gall, S., Lemonnier, F. & Heard, J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2, 338–342 (1996).

    Article  CAS  Google Scholar 

  12. Collins, K.L., Chen, B.K., Kalams, S.A., Walker, B.D. & Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397–401 (1998).

    Article  CAS  Google Scholar 

  13. Martin, M.P. et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733–740 (2007).

    Article  CAS  Google Scholar 

  14. Le Gall, S. et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8, 483–495 (1998).

    Article  CAS  Google Scholar 

  15. Jennes, W. et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 177, 6588–6592 (2006).

    Article  CAS  Google Scholar 

  16. Martin, M.P. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429–434 (2002).

    Article  CAS  Google Scholar 

  17. Morvan, M. et al. Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J. Immunol. 182, 6727–6735 (2009).

    Article  CAS  Google Scholar 

  18. Champsaur, M. & Lanier, L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267–285 (2010).

    Article  CAS  Google Scholar 

  19. Fogli, M. et al. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog. 4, e1000101 (2008).

    Article  Google Scholar 

  20. Ward, J. et al. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog. 5, e1000613 (2009).

    Article  Google Scholar 

  21. Schröfelbauer, B., Yu, Q., Zeitlin, S.G. & Landau, N.R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79, 10978–10987 (2005).

    Article  Google Scholar 

  22. Mansky, L.M., Preveral, S., Selig, L., Benarous, R. & Benichou, S. The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J. Virol. 74, 7039–7047 (2000).

    Article  CAS  Google Scholar 

  23. Cerboni, C. et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J. Gen. Virol. 88, 242–250 (2007).

    Article  CAS  Google Scholar 

  24. Russell, R.A. & Pathak, V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201–8210 (2007).

    Article  CAS  Google Scholar 

  25. Gasser, S., Orsulic, S., Brown, E. & Raulet, D. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186–1190 (2005).

    Article  CAS  Google Scholar 

  26. Branzei, D. & Foiani, M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 9, 297–308 (2008).

    Article  CAS  Google Scholar 

  27. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152–9159 (2004).

    Article  CAS  Google Scholar 

  28. Mansky, L.M., Preveral, S., Selig, L., Benarous, R. & Benichou, S. The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. J. Virol. 74, 7039–7047 (2000).

    Article  CAS  Google Scholar 

  29. Casartelli, N. et al. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 207, 39–49 (2009).

    Article  Google Scholar 

  30. Gourzi, P., Leonova, T. & Papavasiliou, F.N. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 24, 779–786 (2006).

    Article  CAS  Google Scholar 

  31. Maasho, K., Opoku-Anane, J., Marusina, A.I., Coligan, J.E. & Borrego, F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J. Immunol. 174, 4480–4484 (2005).

    Article  CAS  Google Scholar 

  32. Schrader, C.E., Linehan, E.K., Mochegova, S.N., Woodland, R.T. & Stavnezer, J. Inducible DNA breaks in Ig S regions are dependent on AID and UNG. J. Exp. Med. 202, 561–568 (2005).

    Article  CAS  Google Scholar 

  33. Stenglein, M.D., Burns, M.B., Li, M., Lengyel, J. & Harris, R.S. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17, 222–229 (2010).

    Article  CAS  Google Scholar 

  34. Altan-Bonnet, G. & Libchaber, A. Bubble dynamics in double-stranded DNA. Phys. Rev. Lett. 90, 138101 (2003).

    Article  Google Scholar 

  35. Sire, J., Quérat, G., Esnault, C. & Priet, S. Uracil within DNA: an actor of antiviral immunity. Retrovirology 5, 45 (2008).

    Article  Google Scholar 

  36. Priet, S. et al. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol. Cell 17, 479–490 (2005).

    Article  CAS  Google Scholar 

  37. Yang, B., Chen, K., Zhang, C., Huang, S. & Zhang, H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11667–11675 (2007).

    Article  CAS  Google Scholar 

  38. Pauli, E.-K. et al. High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity. Retrovirology 6, 38 (2009).

    Article  Google Scholar 

  39. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–1529 (2004).

    Article  CAS  Google Scholar 

  40. Collins, K.L. & Baltimore, D. HIV's evasion of the cellular immune response. Immunol. Rev. 168, 65–74 (1999).

    Article  CAS  Google Scholar 

  41. Lahm, H.W. & Stein, S. Characterization of recombinant human interleukin-2 with micromethods. J. Chromatogr. A 326, 357–361 (1985).

    Article  CAS  Google Scholar 

  42. Schaefer, M.R., Wonderlich, E.R., Roeth, J.F., Leonard, J.A. & Collins, K.L. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog. 4, e1000131 (2008).

    Article  Google Scholar 

  43. Qin, X.-F., An, D.S., Chen, I.S.Y. & Baltimore, D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 100, 183–188 (2003).

    Article  CAS  Google Scholar 

  44. Galbán, S. et al. Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochem. J. 417, 765–771 (2009).

    Article  Google Scholar 

  45. Zhang, H. et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78, 1718–1729 (2004).

    Article  CAS  Google Scholar 

  46. Carter, C.C. et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat. Med. 16, 446–451 (2010).

    Article  CAS  Google Scholar 

  47. Nakai-Murakami, C. et al. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 26, 477–486 (2007).

    Article  CAS  Google Scholar 

  48. Yamamoto, N. et al. Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes 32, 105–113 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health; M. Gately (Hoffmann La Roche) for human recombinant interleukin 2; H. Zhang, Y. Zhou and R. Siliciano (Johns Hopkins University) for pNL4-3-ΔE-EGFP (11100); K. Strebel (National Institute of Allergy and Infectious Diseases, US National Institutes of Health) for A3G antiserum (ApoC17); M.H. Malim (King's College London) for monoclonal antibody 319 to HIV-1 Vif; BioMolecular Technologies for antiserum to HIV-1SF2 p24; and the University of Michigan Flow Cytometry core, Sequencing Core (US National Institutes of Health grant P30CAO46592) and Hybridoma Core (US National Institutes of Health grant P30AR048310) and the Center for Statistical Consultation for services. Supported by US National Institutes of Health (R01 AI051192; T32GM007863 and T32AI007413 to M.M.; and UL1RR024986 (National Center for Research Resources) to A.O.-N.), US National Science Foundation (DGE 0718128 to L.A.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of National Center for Research Resources or the US National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA

    Jason M Norman, Lucy A McNamara & Kathleen L Collins

  2. Graduate Program in Immunology, University of Michigan, Ann Arbor, Michigan, USA

    Michael Mashiba & Kathleen L Collins

  3. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA

    Lucy A McNamara

  4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

    Adewunmi Onafuwa-Nuga, Estelle Chiari-Fort, Wenwen Shen & Kathleen L Collins

Authors
  1. Jason M Norman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Mashiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucy A McNamara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adewunmi Onafuwa-Nuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Estelle Chiari-Fort
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenwen Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kathleen L Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.M.N. and K.L.C. designed the experiments and prepared the manuscript; J.M.N., M.M., L.A.M., A.O.-N., W.S. and E.C.-F. did experiments; and all authors read and edited the manuscript.

Corresponding author

Correspondence to Kathleen L Collins.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–2 and Tables 1–3 (PDF 526 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Norman, J., Mashiba, M., McNamara, L. et al. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 12, 975–983 (2011). https://doi.org/10.1038/ni.2087

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ni.2087

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing